The analysis of a pilot panel of ovarian cancer cases (63 cancer patients and 50 controls) did indeed show that several ovarian cancer patients exhibited extremely high levels of claudin-4 in the plasma, while control individuals did not typically show elevated amounts of this protein (Figure 4). Here, CLDN4 is linked to ovarian carcinoma.